anti-CD19 CAR T-cell therapy (First Hospital of Jilin University)

N/A

Report date: 2025/01/26 16:53:28

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (First Hospital of Jilin University)
Drug Alias Namesecond generation CAR-T cell therapy (First Hospital of Jilin University)anti-CD19 scFv CAR T-cell therapy (First Hospital of Jilin University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesFirst Hospital Of Jilin University
China Registration ClassN/A

Develop Information

Active CompaniesFirst Hospital Of Jilin University
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A